First Procedure in Phase 2 Clinical Trial of Mesoblast’s Adult Mesenchymal Precursor Cell (MPC) Product
Dr. Kenneth Pettine of The Spine Institute in Loveland, CO successfully performed the first minimally invasive lumbar disc procedure in the Phase 2 clinical trial of Mesoblast’s investigational adult Mesenchymal Precursor Cell (MPC) product for low back pain and degenerative disc disease. The outpatient procedure lasted less than 20 minutes, with the patient fully awake and under light sedation. The patient was shortly discharged and there were no complications.
The procedure took place at The Spine Institute and Loveland Surgery Center in Colorado, a United States Spine Center of Excellence. Dr. Pettine is a founder of The Spine Institute, an international leader in non-fusion surgery of the spine, and the co-inventor of Medtronic’s Maverick artificial lumbar disc device.
“This marks the third renaissance in spine care,” Dr. Pettine said. “The first was improved diagnosis using Magnetic Resonance Imaging (MRI), the second was end-stage replacement with artificial discs, and now there is the potential widespread use of adult stem cells for disc repair and regeneration.”
Up to 15 percent of people in industrialized countries have chronic low back pain lasting more than six months. For those with progressive, severe and debilitating pain due to ongoing progression of disc degeneration, the only option is major back surgery involving artificial disc replacement or spinal fusion. Both types of surgery are associated with significant risks, and the avoidance of surgery is a major objective of new treatments for degenerative disease of the spine.
Building on these results, Mesoblast aims to show that a single minimally invasive injection of its allogeneic, or off-the-shelf, disc repair MPC product can regenerate damaged discs, thereby reducing pain, improving function, and avoiding surgery. Mesoblast’s Phase 2 trial, which was cleared by the United States Food and Drug Administration (FDA) in July, will enroll 100 patients with chronic low back pain due to lumbar disc degeneration in 15 centers across the United States and Australia, comparing outcomes at six months in 60 patients receiving MPC injections against 40 patients receiving control injections.
“There is a significant need for a minimally invasive biological solution to repair the degenerating disc, reduce back pain, improve function, and eliminate the need for surgery. Mesoblast’s adult stem cell product could find broad use in the treatment of both early and late degenerative disc disease, and could additionally reduce spine surgery for this condition by as much as 80 percent,” Dr. Pettine added.
Those interested in becoming a candidate for the Phase 2 clinical trial are encouraged to contact The Spine Institute at 800-795-5487 or 970-669-8881.
Spine Institute Home
Spine Institute Home
